Electromed Net Worth
Electromed Net Worth Breakdown | ELMD |
Electromed Net Worth Analysis
Electromed's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Electromed's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Electromed's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Electromed's net worth analysis. One common approach is to calculate Electromed's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Electromed's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Electromed's net worth. This approach calculates the present value of Electromed's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Electromed's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Electromed's net worth. This involves comparing Electromed's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Electromed's net worth relative to its peers.
Enterprise Value |
|
To determine if Electromed is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Electromed's net worth research are outlined below:
Electromed appears to be risky and price may revert if volatility continues | |
About 28.0% of the company shares are held by company insiders | |
Latest headline from investing.com: Electromed director Kathleen Skarvan sells shares worth 4.2 million |
Electromed uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Electromed. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Electromed's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
13th of February 2024 Upcoming Quarterly Report | View | |
31st of December 2023 Next Fiscal Quarter End | View |
Follow Electromed's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 251.96 M.Market Cap |
|
Project Electromed's profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.10 | 0.10 | |
Return On Capital Employed | 0.15 | 0.08 | |
Return On Assets | 0.10 | 0.10 | |
Return On Equity | 0.12 | 0.06 |
When accessing Electromed's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Electromed's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Electromed's profitability and make more informed investment decisions.
Please note, the presentation of Electromed's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Electromed's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Electromed's management manipulating its earnings.
Evaluate Electromed's management efficiency
Electromed has return on total asset (ROA) of 0.0839 % which means that it generated a profit of $0.0839 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1253 %, meaning that it created $0.1253 on every $100 dollars invested by stockholders. Electromed's management efficiency ratios could be used to measure how well Electromed manages its routine affairs as well as how well it operates its assets and liabilities. At present, Electromed's Return On Assets are projected to increase slightly based on the last few years of reporting. At present, Electromed's Return On Assets are projected to increase slightly based on the last few years of reporting.Last Reported | Projected for Next Year | ||
Book Value Per Share | 5.20 | 5.46 | |
Tangible Book Value Per Share | 5.13 | 5.38 | |
Enterprise Value Over EBITDA | 14.17 | 14.88 | |
Price Book Value Ratio | 2.72 | 2.65 | |
Enterprise Value Multiple | 14.17 | 14.88 | |
Price Fair Value | 2.72 | 2.65 | |
Enterprise Value | 105.2 M | 110.4 M |
Electromed has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 4.1728 | Revenue 54.7 M | Quarterly Revenue Growth 0.09 | Revenue Per Share 6.39 | Return On Equity 0.1253 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Electromed insiders, such as employees or executives, is commonly permitted as long as it does not rely on Electromed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Electromed insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Electromed Corporate Filings
F3 | 21st of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
F4 | 20th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 13th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Electromed Earnings per Share Projection vs Actual
Electromed Corporate Management
Amy Yanta | Quality Affairs | Profile | |
Brad Nagel | Chief Officer | Profile | |
Diane Kaufman | Vice Resources | Profile | |
William George | Secretary | Profile | |
Christopher Holland | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Electromed. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Electromed Stock refer to our How to Trade Electromed Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Electromed. If investors know Electromed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Electromed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.809 | Earnings Share 0.72 | Revenue Per Share 6.39 | Quarterly Revenue Growth 0.09 | Return On Assets 0.0839 |
The market value of Electromed is measured differently than its book value, which is the value of Electromed that is recorded on the company's balance sheet. Investors also form their own opinion of Electromed's value that differs from its market value or its book value, called intrinsic value, which is Electromed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Electromed's market value can be influenced by many factors that don't directly affect Electromed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Electromed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Electromed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Electromed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.